Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant

Cancer Treatment and Research Communications - Tập 32 - Trang 100587 - 2022
Ayumi Saito1, Maki Tanioka1, Makoto Hirata2, Tomoko Watanabe2, Yoko Odaka3, Tatsunori Shimoi1, Kazuki Sudo1, Emi Noguchi1, Mitsuya Ishikawa4, Kan Yonemori1
1Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
3Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
4Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan

Tài liệu tham khảo

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 209, 10.3322/caac.21660

Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare) https://ganjoho.jp/reg_stat/statistics/data/dl/index.html [Accessed August 28, 2021].

Enomoto, 2019, The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE), Int. J. Gynecol. Cancer, 29, 1043, 10.1136/ijgc-2019-000384

Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 17, 1152, 10.1126/science.aam7344

Tew, 2020, PARP inhibitors in the management of ovarian cancer: ASCO guideline, J. Clin. Oncol., 38, 3468, 10.1200/JCO.20.01924

Ricci A.D., Rizzo A., Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box? ESMO open (2020) 5(5):e001042 [PMID: 32994319 PMCID: PMC7526276 doi: 10.1136/esmoopen-2020-001042].

Moghadasi, 2018, The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium, J. Med. Genet., 55, 15, 10.1136/jmedgenet-2017-104560

Yoshihama, 2021, Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome, Int. Cancer Conf. J., 10, 6, 10.1007/s13691-020-00449-9

Richards, 2015, ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet. Med., 17, 405, 10.1038/gim.2015.30

Coleman, 2019, Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer, N. Engl. J. Med., 381, 2403, 10.1056/NEJMoa1909707

Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol., 18, 1274, 10.1016/S1470-2045(17)30469-2

Coleman, 2017, Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 28, 1949, 10.1016/S0140-6736(17)32440-6

Coquelle, 2011, Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition, Biochemistry, 50, 4579, 10.1021/bi2003795

Lovelock, 2007, Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?, Breast Cancer Res., 9, R82, 10.1186/bcr1826

Dias, 2021, Understanding and overcoming resistance to PARP inhibitors in cancer therapy, Nat. Rev. Clin. Oncol., 18, 773, 10.1038/s41571-021-00532-x

Lheureux, 2017, Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization, Clin. Cancer Res., 23, 4086, 10.1158/1078-0432.CCR-16-2615

Thông tin
Thông tin xuất bản

Cancer Treatment and Research Communications

Tập 32

100587

Thông tin tác giả